EA202193257A1 - Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы - Google Patents

Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы

Info

Publication number
EA202193257A1
EA202193257A1 EA202193257A EA202193257A EA202193257A1 EA 202193257 A1 EA202193257 A1 EA 202193257A1 EA 202193257 A EA202193257 A EA 202193257A EA 202193257 A EA202193257 A EA 202193257A EA 202193257 A1 EA202193257 A1 EA 202193257A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
breast cancer
application
cancer treatment
leuprolide acetate
Prior art date
Application number
EA202193257A
Other languages
English (en)
Russian (ru)
Inventor
Джон Миддлтон
Авинаш Нангия
Джон Артур Маклейн
Терри Л. Мортон
Original Assignee
Толмар Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Толмар Интернэшнл Лимитед filed Critical Толмар Интернэшнл Лимитед
Publication of EA202193257A1 publication Critical patent/EA202193257A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
EA202193257A 2019-05-27 2020-05-26 Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы EA202193257A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
PCT/IB2020/054984 WO2020240417A1 (en) 2019-05-27 2020-05-26 Leuprolide acetate compositions and methods of using the same to treat breast cancer

Publications (1)

Publication Number Publication Date
EA202193257A1 true EA202193257A1 (ru) 2022-03-10

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193257A EA202193257A1 (ru) 2019-05-27 2020-05-26 Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы

Country Status (17)

Country Link
US (2) US12453754B2 (cg-RX-API-DMAC7.html)
EP (1) EP3975990A1 (cg-RX-API-DMAC7.html)
JP (1) JP7664855B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220041782A (cg-RX-API-DMAC7.html)
CN (1) CN114144169A (cg-RX-API-DMAC7.html)
AR (1) AR119021A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020284587B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023904A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141456A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193257A1 (cg-RX-API-DMAC7.html)
IL (1) IL288503A (cg-RX-API-DMAC7.html)
MX (1) MX2021014540A (cg-RX-API-DMAC7.html)
PH (1) PH12021552976A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112888RA (cg-RX-API-DMAC7.html)
TW (1) TWI757753B (cg-RX-API-DMAC7.html)
UY (1) UY38717A (cg-RX-API-DMAC7.html)
WO (1) WO2020240417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112888RA (en) 2019-05-27 2021-12-30 Tolmar International Ltd Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR102742097B1 (ko) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 혼합 주사기 밸브 어셈블리를 위한 시스템 및 방법
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2637569C (en) * 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
EP3202814B1 (en) * 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
SG11202112888RA (en) 2019-05-27 2021-12-30 Tolmar International Ltd Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
KR102742097B1 (ko) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 혼합 주사기 밸브 어셈블리를 위한 시스템 및 방법
AU2022331238A1 (en) 2021-08-19 2024-02-01 Carefusion 303, Inc. Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Also Published As

Publication number Publication date
IL288503A (en) 2022-01-01
US20220265760A1 (en) 2022-08-25
AU2020284587B2 (en) 2025-09-18
CN114144169A (zh) 2022-03-04
US20260027176A1 (en) 2026-01-29
AR119021A1 (es) 2021-11-17
KR20220041782A (ko) 2022-04-01
US12453754B2 (en) 2025-10-28
PH12021552976A1 (en) 2022-07-04
UY38717A (es) 2020-11-30
TWI757753B (zh) 2022-03-11
TW202110472A (zh) 2021-03-16
SG11202112888RA (en) 2021-12-30
JP2022535694A (ja) 2022-08-10
MX2021014540A (es) 2022-04-12
BR112021023904A2 (pt) 2022-02-01
JP7664855B2 (ja) 2025-04-18
WO2020240417A1 (en) 2020-12-03
CA3141456A1 (en) 2020-12-03
AU2020284587A1 (en) 2022-01-06
EP3975990A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
CL2019003266A1 (es) Anticuerpos anti-sirpalfa.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
EA202092306A1 (ru) Анти-cd24 композиции и их применения
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
EA202092605A1 (ru) Антитела к ил-11ra
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
PE20210289A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
MX2021014286A (es) Proteinas multiespecificas.
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX2022002682A (es) Anticuerpos anti-cd73.
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
CL2017003131A1 (es) Terapia de combinación para el tratamiento de cáncer
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL280145A (en) Methods and compositions using recombinant dendritic cells for cancer therapy
EA201592203A1 (ru) Способы лечения таупатии
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2021014540A (es) Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama.